Exelixis Reports Third Quarter Revenues of $597.8 Million
Reuters
Nov 05
Exelixis Reports Third Quarter Revenues of $597.8 Million
Exelixis Inc. reported total revenues of $597.8 million for the third quarter ended September 30, 2025, up from $539.5 million in the same period in 2024. Net product revenues for the quarter were $542.9 million, compared to $478.1 million in the prior year period, primarily due to increased sales volume. For fiscal year 2025, Exelixis updated its financial guidance, projecting total revenues between $2.3 billion and $2.35 billion and net product revenues of $2.1 billion to $2.15 billion. Research and development expenses are expected to be $850 million to $900 million, while selling, general and administrative expenses are projected at $500 million to $525 million. Cost of goods sold is estimated at approximately 4% of net product revenues. The company also reported progress in zanzalintinib pivotal trials and phase 1 clinical studies from its early-stage pipeline.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251103969820) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.